INTRODUCTION
Human immune deficiency virus type 2 (HIV-2) is endemic in West Africa and has spread elsewhere in countries with historical and socioeconomic ties to this region [1, 2] . In West Africa, HIV-2 infection accounts for 10-20% of all HIV infections, with a significant proportion of coinfections with both HIV-1 and HIV-2 [3, 4] . In the last decade, many studies reported a consistent decline in the prevalence of HIV-2 infection in West Africa, especially in The Gambia and Guinea-Bissau but the reasons of these epidemiological changes remain unclear [5, 6] . However, new HIV-2 infections are still diagnosed.
Cohorts of people living with HIV-2 are less common worldwide than for those living with HIV-1 [3, 7] . Clinically, people living with HIV-2 experience a longer asymptomatic latency period and a slower disease progression than those infected with HIV-1 [8] . In addition, their biological progression is characterized by a slower T lymphocyte CD4 (CD4) depletion [9, 10] and a lower plasma viral load compared with HIV-1 [11, 12] . However, HIV-2infected patients can develop AIDS disease [13, 14] and death [15, 16] , if they do not receive any antiretroviral therapy (ART).
The consolidated 2013 World Health Organization (WHO) guidelines recommended to initiate ART among HIV-2-infected patients with either three nucleoside reverse transcriptase inhibitors (NRTIs) or two NRTIs and one protease inhibitor [17] . However, the application of these guidelines could lead to the unavailability of effective secondline agents in areas with limited access to ART, as phenotypic cross-resistance with protease inhibitors as well as NRTIs is a significant issue for HIV-2 [18, 19] . More recently, the 2015 WHO guidelines recommended ART initiation in all people living with HIV, including those infected with HIV-2, regardless of CD4 cell count or clinical disease progression [20] . The general aim of these guidelines was to reduce HIV transmission and improve survival, as both benefits of early ART initiation have now been clearly demonstrated [21] . However, the strict implementation of these recommendations could be challenging, as people living with HIV-2 usually present with high CD4 cell counts for a long period. Furthermore, the full impact evaluation of such guidelines will have to rely on the measurement of disease-free survival or its counter-measures, loss to follow up and mortality. This review aims to report on the mortality rates, survival patterns and their sociodemographic, clinical and biological predictors among people living with HIV-2 infected either with ART or not.
SEARCH STRATEGY AND SELECTION CRITERIA
Considering the limited number of publications on the epidemiology of HIV-2 infection, we have not restricted the period of the review.
Eligibility criteria
All studies, regardless of design, place or language restrictions, were considered if they met the following three selection criteria: data on HIV-2-infected patients clearly disaggregated, data on mortality (death or survival) and 3) abstract, article and oral or poster presentation available. We included all studies reporting treatment outcomes, mortality or survival among HIV-2 only and HIV-1/HIV-2 dually infected patients. We excluded case series with less than five patients.
Search strategy and study selection
We developed a sensitive search strategy that combined terms for HIV-2 and mortality.
(''hiv-2''[MeSH Terms] OR ''hiv-2''[All Fields] OR ''hiv 2''[All Fields]) AND (''mortality''[Subheading] OR ''mortality''[All Fields] OR ''mortality''[MeSH Terms]).
Searches were conducted in the following databases: MEDLINE via PubMed and EMBASE. Additional articles were identified from references cited in published papers. We also searched the abstracts available from International AIDS Society conferences, Conferences on Retroviruses and Opportunistic Infections and International Conferences for AIDS in Africa in the preceding 12 months. Searches were completed up to December 2015.
Outcome measures and data analysis
The outcomes of interest were mortality and survival estimates at different time points. We also looked for factors associated with mortality or survival. We described each relevant study, and analyzed the outcomes reported in each study. When possible, we used the reported data to compute 95% confidence intervals (CIs) for mortality estimates.
MORTALITY ESTIMATES IN PEOPLE LIVING WITH HIV-2

Mortality before antiretroviral therapy initiation
It is often stated that about 80% of people living with HIV-2 behave like HIV-1 long-term nonprogressors and elite controllers, keeping high CD4 cell count (500 cells/mm 3 ) and low or undetectable viral load (100 copies/ml) for up to 5-10 years [22, 23] . Several reports on pre-ART mortality among people living with HIV-2 were available, primarily from West Africa, with most data available from The Gambia [24] [25] [26] and Guinea-Bissau [16, [27] [28] [29] with overlapped populations over the time. None of these reports was published during the last 12 months ( ]. The main conclusion drawn from these articles is that compared with people living with HIV-1, those living with HIV-2 and followed in the same settings have a lower crude mortality rate 
KEY POINTS
Before ART initiation, people living with HIV-2 and more than 500 CD4 cells/mm 3 survive longer than HIV-1 and HIV1þ2 dually infected patients.
People living with HIV-2 on ART experience high mortality, although lower than compared with HIV-1 individuals owing mostly but not entirely to the age difference at ART initiation.
Data on mortality among people living with HIV-2 remain scarce, emphasizing the need for more collaborative works to estimate the survival and mortality patterns among people living with HIV-2. [25] . More recently, in 2011, the same trends were reported in a rural community of Bissau: the mortality rate was estimated at 4.1 (3.4-5.0) per 100 person-years among the 285 people living with HIV-2 versus 9.6 (7.1-12.9) among 117 people living with HIV-1, whereas it was as low as 1.6 (1.5-1.8) among 4797 HIV-negative individuals [28] . Another study from The Gambia in 2011 reported no difference in terms of mortality according to HIV type when adjusted on CD4 cell count strata (100 versus >100 cells/mm 3 ). This is consistent with a previous report in 2002 suggesting that in the same setting, the lower pre-ART mortality risk in people living with HIV-2 compared with HIV-1 was no longer observed when the CD4 cell count decreased below 500 cells/mm 3 [25] . Thus, without ART, people living with HIV-2 experience moderately higher mortality than HIVnegative individuals and survive longer than people living with HIV-1 when their CD4 cell counts are high (>500 cells/mm 3 ). On the basis of these findings, the question of when to start ART in people living with HIV-2 with high CD4 cell count could be discussed.
Mortality of people living with HIV-2 receiving antiretroviral therapy
Mortality and loss to follow up are the most important outcomes to evaluate the impact of ART in sub-Saharan Africa settings. With the rapid scaling up of ART, mortality has been widely explored in HIV-1-infected patients receiving ART [31] [32] [33] ]. Considering the difference in pathogenicity between HIV-1 and HIV-2, a lower mortality rate could be expected in people living with HIV-2 on ART compared with those living with HIV-1. In Europe, the ACHIE 2 VE collaboration, which is a pooled dataset of seven cohorts, has reported vital status information on 170 people living with HIV-2 among which 44 (26%) received a triple NRTI regimen and 126 (74%) a protease inhibitor boosted by ritonavir (protease inhibitor/r)-based regimen [36] . None of these 170 patients receiving the two WHO recommended HIV-2 treatment options died during the first 12 months of treatment. A previous report from the ANRS CO5 HIV-2 Cohort followed up in France and included in the ACHIE 2 VE collaboration had indicated that the initial CD4 cell count level was a predictor of survival. Thus, patients initiating ART with a median CD4 cell count of 136 cells/ml showed a median CD4 cell increase of 41 cells/ml at month 12, and five (8.1%) deaths were reported after 21 months of follow-up [40] . Another report in the same cohort but focusing only on patients starting a lopinavir/r-based ART regimen for a median duration of 105 weeks [interquartile range (IQR) (39-132)] reported two deaths among 18 patients classified stage A of the center for disease control (CDC) classification [41] . These results obtained in the European context with wide ART availability and use indicate that when treated with recommended ART regimens, people living with HIV-2 have a lower immune recovery than HIV-1 patients and a low overall mortality.
An analysis was recently conducted among people living with HIV-2 followed up in the cohort collaboration of the international epidemiologic database to evaluate AIDS in West Africa (IeDEA-WA) [37 & ]. This data set consisted of 5193 people living with HIV-2 or with both HIV-1 and HIV-2, followed up in seven countries (Benin, Burkina Faso, Côte d'Ivoire, Guinea-Bissau, Mali, Senegal and Togo). Among the 1825 HIV-2 monoinfected patients who initiated ART between February 1997 and September 2014 and were followed up till December 2014, the median CD4 cell count at ART initiation was 263 /mm 3 [IQR (159-429)]. The estimated risks of death after 6, 12 and 24 months on ART were 4.1 (CI: 3.2-5.1), 5.5% (CI: 4.4-6.5) and 7.7% (CI: 6.4-8.9), respectively [37 & ]. In addition, patients lost to follow up were censored after their last contact and the estimated risks of loss to follow up after 6, 12 and 24 months on ART were 10.9% (CI: 9.4-12.3), 16 .7% (CI: 14.9-18.4) and 25.7% (CI: 23.7-27.7), respectively [37 & ].
Another cohort from The Gambia has included 51 HIV-2 and 308 HIV-1 ART-treated individuals with a median follow-up duration of 20.3 months (IQR: 10.0-33.0) and 12.1 months (IQR: 4.9-30.1), respectively. The crude mortality rate while on ART was significantly lower in HIV-2-infected patients compared with the HIV-1 ones (64.2 versus 120.9 per 1000 person years; P ¼ 0.05). The survival probability was 96.0% at 12 months, 89.1% at 24 months and 79.5% at 36 months for people living with HIV-2 on ART, whereas it was 79.7, 72.0 and 72.0 at the same time points for people living with HIV-1 [38] .
In an urban district hospital in Burkina-Faso, Harries et al. [39] investigated mortality among 4255 people living with HIV who initiated ART and were followed up for a median of 22.6 months (IQR: 7.7-39.4). In this population, after a median follow-up on ART of 23 months (IQR: 8-34), the mortality hazard ratios were 1.41 (CI: 0.83-2.41) and 1.32 (CI: 0.80-2.17) for patients living with HIV-1 and those living with HIV-2, respectively, with no statistical significance. The possible explanation could be the administration of inappropriate ART regimen, and the relatively small number of people living with HIV-2 in the cohort, leading to a lack of statistical power [39] .
Factors associated with mortality among people living with HIV-2
As in the general population, the advanced age at diagnosis and at treatment initiation plays an important role in the mortality of people living with HIV-2, either on ART or ART-naive. Many studies including a meta-analysis on pre-ART HIV-2-infected individuals identified being age at least 45 years as the main explanatory factor for mortality among HIV-2-infected individuals [25,28,30 & ]. This effect of an older age seems to be not specific to HIV-2-infected individuals, as similar but higher mortality rates have also been reported in older HIV-1-infected patients. In addition, older age has been shown to be associated with clinical progression to AIDS among ART-naive HIV-2-infected individuals, emphasizing the importance of early diagnosis and treatment initiation [13] . Low CD4 cell count and high plasma viral load are also associated with disease progression and mortality among HIV-2-infected patient [13, 27, 29] , and are usually worse in HIV-2-infected men than women, explaining a part of the sex difference observed in mortality [25,30 & ]. Regarding people living with HIV-2 on ART, the IeDEA West Africa collaboration identified male sex [adjusted hazard ratio (aHR): 1.9; CI: 1.4-2.8; P<0.001], age above or equal to 50 years (aHR: 1.44; CI: 0.9-2.1), CD4 cell count at ART initiation less than 200 cells/mm 3 (aHR: 3.3; CI: 1.3-7.8), body mass index less than 18 kg/m 2 [aHR ¼ 2.1; 95% CI (1.2-3.4), P-value ¼ 0.005] and hemoglobin rate less than 10 g/dl [aHR 2.4; 95% CI (1.3-4.4); P-value ¼ 0.005] as factors associated with higher mortality (P ¼ 0.001) [37 & ]. In The Gambia, Peterson et al. [38] identified CD4 cell count less than 50 per ml (aHR ¼ 2.3; CI: 1.2-4.5 P ¼ 0.02), hemoglobin level less than 8.0 g/dl (aHR: 6.2; CI: 2.8-13.8; P < 0.001), weight less than 45 kg (aHR: 3.9; CI: 1.8-8.2; P < 0.001) and male sex (aHR: 4.9; CI: 2.5-10.8; P < 0.001) as factors associated with mortality among people living with HIV-2 and receiving ART. Finally, mortality in people living with HIV-2 either ART naive and on ART seems to be associated with the same factors than in HIV-1 mortality, including age, sex, clinical and laboratorial baseline characteristics [38, 39, 42, 43] . However, the role of immune activation in the mortality and sex difference among HIV-2-infected individuals remains unclear and further investigations are needed [44] .
Reliability of mortality estimates among people living with HIV-2 on antiretroviral therapy
Data on mortality and survival among people living with HIV-2 remain limited in size and quality. When available, they are usually presented as crude mortality rates [34 & ,35, 36, 40] , and very few are using the most appropriate statistical methods [25, 39] . Most of the cohorts lacked power to detect any statistical difference when investigating factors associated with mortality and some of them lumped together HIV-2 and HIV-1 þ HIV-2 dually reactive patients. The few studies including people living with HIV-2 on ART with survival analyses did not describe high early mortality figures as observed in HIV-1-infected patients [45] . In the report of the IeDEA West Africa collaboration, the largest ever for ART-treated people living with HIV-2, mortality seems underestimated because of the high number of patients lost to follow as already described in HIV-1 patients in the West Africa region [46] . No cohort of HIV-2-infected patients reported having implemented an active search in case of loss to follow up as often done for HIV-1 patients [47] . Finally, the causes of death have not been usually reported in the studies we reviewed, and the all-cause mortality is probably insufficient to provide an insight of what could be an HIV-2-specific mortality pattern.
CONCLUSION
Despite the low disease progression, the rate of death for people living with HIV-2 receiving ART is elevated, especially for those enrolled and followed in the West African context. Thus, it cannot be considered very different from what is known for patients infected with HIV-1 or dual infection and living in the same environment. One of the reasons explaining the high rate of mortality among people living with HIV-2 is the late presentation, characterized by the older age at ART initiation (8-10 years difference between HIV-2 and HIV-1) with low CD4 cell count and high plasma viral load [34 There is a need to better document the causes of death among people living with HIV-2 and to explore further treatment adherence and viral resistance on ART. The low mortality hypothesis often formulated for HIV-2 patients seems to hold in the pre-ART era but not beyond, because of a combination of factors. Now that the when to start question has been normalized irrespective of the HIV type [20] , the question of what to start remains for HIV-2 patients [34 & ] and is likely to be the last frontier to improve their prognosis.
